Eurobio Scientific: 2024 annual results

Core Business Growth - Eurobio Scientific reported a revenue increase of 19% to €154.2 million in 2024, compared to €130 million in 2023, with organic growth at 9% [4][5][6] - Proprietary products accounted for 31% of total sales, remaining stable compared to the previous year, while international sales represented 41% of group revenue, up from 38% in 2023 [5][6] Financial Performance - Total operating income rose by 19% to €154.9 million, with a gross margin of 46.6%, down approximately 1% from 2023 due to pressure on margins and challenges faced by some European subsidiaries [4][7] - Adjusted EBITDA was €27.7 million, a slight increase from €27.3 million in 2023, while operating income was stable at €22.1 million [10][11] Cost Management - Research and development expenses decreased to €4.6 million, primarily due to reduced activity in France, while marketing and sales expenses increased by €10.1 million, driven by strengthening sales teams and new acquisitions [8] - General and administrative expenses rose by €1.8 million, attributed to new premises and acquisitions [8] Strategic Developments - The company completed the acquisition of EndoPredict® and Prolaris® in August 2024, generating sales of €3.8 million, although this was a 10% decline compared to 2023 [9] - Eurobio Scientific is focused on strategic priorities including the development of proprietary products, internationalization, and market expansion to enhance growth in sales and margins [16] Cash Flow and Debt Management - Free cash flow for 2024 was €6 million, with cash flow from operations amounting to €16.7 million [12][13] - At the end of December 2024, the company had cash and cash equivalents of €23.1 million and net debt of €3.9 million [15]